Sugimoto, Yoshikazu

J-GLOBAL         Last updated: Aug 2, 2019 at 04:57
 
Avatar
Name
Sugimoto, Yoshikazu
URL
http://www.pha.keio.ac.jp/laboratory/laboratory15/index.html
Affiliation
Keio University
Section
Faculty of Pharmacy Department of Pharmacy
Job title
Professor
Research funding number
10179161

Research Areas

 
 

Education

 
Mar 1980
   
 
薬学科, Faculty of Pharmaceutical Science, The University of Tokyo
 
Mar 1985
   
 
生命薬学専攻, Graduate School of Pharmaceutical Sciences, The University of Tokyo
 

Published Papers

 
Synthesis of 5-hydroxy-3’,4’,7-trimethoxyflavone (HTMF) and related compounds and elucidation of their reversal effects on BCRP/ABCG2-mediated anticancer drug resistance.
Tsunekawa R, KatayamaK, Hanaya K, Higashibayashi S, Sugimoto Y, Sugai T.
CalBioChem   20(2) 210-220   Jan 2019   [Refereed]
Fukaya M, Nakamura S, Hegazy MEF, Sugimoto Y, Hayashi N, Nakashima S, Yoshikawa M, Efferth, Matsuda H.
Food Funct   9(12) 6279-6286   Dec 2018   [Refereed]
Mahmoud N, Saeed MEM, Sugimoto Y, Klauck SM, Greten HJ, Efferth T.
Oncotarget   9(87) 35762-35779   Nov 2018   [Refereed]
Kato Y, Kunimasa K, Sugimoto Y, Tomida A.
Biochem Biophys Res Commun   504(4) 721-726   Oct 2018   [Refereed]
Seo EJ, Sugimoto Y, Greten HJ, Efferth T.
Front Pharmacol   9 1030   Oct 2018   [Refereed]

Misc

 
Human ABC transporter ABCG2/BCRP expression in chemoresistance: basic and clinical perspectives for molecular cancer therapeutics.
Noguchi K, Katayama K, Sugimoto Y*.
Pharmacogenomics and Personalized Medicine   7 53-64   Feb 2014
トランスポーターの遺伝子多型.
杉本芳一.
がん分子標的治療   9(3) 29-35   Jul 2011
分子標的薬.
杉本芳一.
薬局   61(2) 11   Feb 2010
抗悪性腫瘍薬の薬理学・薬力学・薬理遺伝学ー薬物相互作用.
杉本芳一.
日本臨床   67, Suppl 1 349-355   Jan 2009
抗癌剤開発における民族差について.
杉本芳一.
臨床評価   33(2) 393-398   Apr 2006   [Refereed]

Books etc

 
がん化学療法・分子標的治療update.
杉本芳一.
中外医学社, 東京   Oct 2009   
がん薬物療法学.
杉本芳一. (Part:Joint Work, 349-355)
大阪/日本臨床社   Jan 2009   
がんの分子標的治療.
'野口耕司, 杉本芳一.' (Part:Joint Work, 278-290)
東京/南山堂   Sep 2008   
薬剤師生涯研修ガイド.
杉本芳一. (Part:Joint Work, 223-224)
東京/学校法人医学アカデミー出版部   May 2008   
薬学の未来を拓く.
杉本芳一. (Part:Joint Work, 72-81)
東京/慶應義塾   Apr 2008   

Conference Activities & Talks

 
BCR-ABL tyrosine kinase inhibition induces metabolic vulnerability by preventing the integrated stress response in K562 cells. [Invited]
Kato K, Kunimasa K, Sugimoto Y, Tomida A.
The 23rd Japanese Foundation for Cancer Research International Symposium on Cancer Chemotherapy   13 Dec 2018   
Heat shock protein 90 inhibitors overcome the resistance to various Fms-like tyrosine kinase 3 inhibitors.
Katayama K, Noguchi K, Sugimoto Y.
The 30th EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium   16 Nov 2018   
Poly (ADP-ribose) polymerase1 deficiency is not correlated with rucaparib and veliparib sensitivity in A2780 cells.
Nonomiya Y, Noguchi K, Katayama K, Sugimoto Y.
The 30th EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium   16 Nov 2018   
IL-10プロモーターにおけるK-RTAとSP1/3の相互作用解析.
宮澤雅典, 野口耕司, 片山和浩, 杉本芳一.
第66回日本ウイルス学会学術集会   29 Oct 2018   
患者由来胃がん細胞におけるCD44v陽性細胞の薬剤抵抗性への寄与とそのメカニズム.
川上隆兵, 馬島哲夫, 熊谷厚志, 杉本芳一, 右田敏郎, 佐野武, 山口研成, 清宮啓之.
第77回日本癌学会学術総会   29 Sep 2018   

Teaching Experience

 

Research Grants & Projects

 
Analysis of the resistance mechanisms to molecular-targeting anticancer agents
MEXT,JSPS: Grant-in-Aid for Scientific Research
Project Year: Apr 2018 - Mar 2021    Investigator(s): 杉本 芳一
Identification of factors regulating the capacity for both self-renewal and pluripotent differentiation of cancer stem cells and application to cancer treatment.
MEXT,JSPS: Grant-in-Aid for Scientific Research
Project Year: Apr 2015 - Mar 2017    Investigator(s): 杉本 芳一
SP(+) cells have a property of Hoechst 33342 exclusion and are considered as stem-like cells. SP(+) cells isolated from human colorectal cancer 116/slug-25 cells showed higher expression of drug efflux transporter ABCG2 and histone acetyl transfer...